Nkarta Inc (NKTX)

Apr 1, 2025, 8:01 AM EDT - 2 days ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 3 days ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 3 days ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 7 days ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 8 days ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 5 weeks ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 4 months ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 4 months ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 5 months ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 8, 2024, 9:07 AM EDT - 6 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Sep 3, 2024, 4:01 PM EDT - 7 months ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 8 months ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 13, 2024, 9:03 PM EDT - 8 months ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 8 months ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 9 months ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 9 months ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 10 months ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 10 months ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 11 months ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 11 months ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 1 year ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 1 year ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 1 year ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 1 year ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 1 year ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 1 year ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 1 year ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 1 year ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jun 27, 2023, 7:01 AM EDT - 1 year ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 1 year ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 1 year ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 2 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

Apr 17, 2023, 5:01 PM EDT - 2 years ago

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Nkarta Announces Departure of Chief Financial & Business Officer

Mar 26, 2023, 6:37 AM EDT - 2 years ago

Nkarta: Going Down Despite Solid Data Due To Fate's Debacle

Mar 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Jan 18, 2023, 1:58 PM EST - 2 years ago

7 Cheap But Risky Biotech Stocks

AFMD BCAB IMRX TIL